Biotechnology Value Fund — 2021 Investments
4 investments dated 2021 · listed companies and verified rows first · show all
BiotechSeattle, US
Mitchell Gold(Executive Chairman and Chief Executive Officer)inMichael Kornacker(Executive Officer, Director)inRyan Swanson(Executive Officer, Director)inDavid Miller(Executive Officer, Director)inJames Paul Rickey(Senior Vice President and Chief Financial Officer)Mark James Litton(President and Chief Operating Officer)
Co-investorsDecheng CapitalFrazier Life SciencesOrbiMed
Exo Therapeutics is a small molecule drug discovery company developing therapeutics through its ExoSight platform, which targets exosites—unique binding pockets on enzymes—to address previously undruggable diseases in oncology, inflammation, and other therapeutic areas.
BiotechDeep TechMedical Devices
David Liu, PhD(Founder)Alan Saghatelian, PhD(Co-Founder)David LiuinAlan Saghetelian
Co-investorsNewpath PartnersCRV (Charles River Ventures)Nextech InvestRaptor GroupSamsara BioCapitalCasdin Capital+1 more
Nimbus develops wireless power technology that uses invisible infrared LED light to transmit energy across a room, with a receiver that converts the light into electricity to charge laptops, phones, and other devices.
Deep TechEnergyHardware
Michael Gorman(Founder)in
Co-investorsFoothill VenturesAccess BiotechnologyAtlas VentureBain Capital Life SciencesCommodore CapitalGV (Google Ventures)+2 more
Other
Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.